Oncimmune Appoints CMO
This article was originally published in Scrip
Oncimmune, a leader in early cancer detection, has named Dr. James Jett chief medical officer. Jett is currently professor of medicine in the division of oncology at National Jewish Health in the US, where his research includes conducting clinical trials related to the screening and early detection of lung cancer. Prior to joining National Jewish Health in 2010, he held appointments as professor of medicine at Mayo Medical School and the University of Pittsburgh.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.